$1.59
2.26% today
Nasdaq, Feb 28, 04:53 pm CET
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Neumora Therapeutics Stock price

$1.55
-0.45 22.50% 1M
-10.01 86.59% 6M
-9.05 85.38% YTD
-17.02 91.65% 1Y
-15.45 90.88% 3Y
-15.45 90.88% 5Y
-15.45 90.88% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.07 4.32%
ISIN
US6409791000
Symbol
NMRA
Sector
Industry

Key metrics

Market capitalization $250.42m
Enterprise Value $-89.35m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.49
P/B ratio (TTM) P/B ratio 0.78
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-250.64m
Free Cash Flow (TTM) Free Cash Flow $-184.08m
Cash position $342.52m
EPS (TTM) EPS $-1.85
P/E forward negative
Short interest 12.01%
Show more

Is Neumora Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Neumora Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Neumora Therapeutics forecast:

Buy
78%
Hold
22%

Financial data from Neumora Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.64 0.64
84% 84%
-
-0.64 -0.64
84% 84%
-
- Selling and Administrative Expenses 55 55
65% 65%
-
- Research and Development Expense 194 194
52% 52%
-
-250 -250
52% 52%
-
- Depreciation and Amortization 0.64 0.64
84% 84%
-
EBIT (Operating Income) EBIT -251 -251
48% 48%
-
Net Profit -294 -294
89% 89%
-

In millions USD.

Don't miss a Thing! We will send you all news about Neumora Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neumora Therapeutics Stock News

Neutral
PRNewsWire
about 20 hours ago
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important ...
Neutral
PRNewsWire
one day ago
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
one day ago
SAN DIEGO , Feb. 26, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant to the Offering Documents issued in connection with the Company's initial public offering ("IPO") on September 15, 2023.  Neumora is a clinical-stage bioph...
More Neumora Therapeutics News

Company Profile

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Head office United States
CEO Paul Berns
Employees 124
Founded 2019
Website www.neumoratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today